Bedrosian Camille L
Chief Medical Officer
Bedrosian Camille L has filed 8 SEC Form 4 filings (10 transaction rows) across 2 companies, including AMLX, CRNX, with disclosures dating back to 2025. 8 of those filings fall inside the rolling window. Most recent filing: Sep 14, 2026.
On the most recent filing, Bedrosian Camille L is listed as Chief Medical Officer at Amylyx Pharmaceuticals, Inc. Inside the rolling window, Bedrosian Camille L reported no open-market purchases and 4 open-market sales totaling $689K in AMLX. The largest disclosed transaction in the window is a sale of 10,028 AMLX shares on Sep 10, 2026, worth $325K.
Companies traded
Other insiders at AMLX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$689K
reported sales (SEC code S)
Companies
2
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Bedrosian Camille L made?
Bedrosian Camille L has filed 8 SEC Form 4 filings (10 transaction rows) across 2 companies, including AMLX, CRNX since 2025.
Which companies does Bedrosian Camille L trade?
Bedrosian Camille L has filed SEC Form 4 disclosures for 2 companies, including AMLX, CRNX.
When was Bedrosian Camille L's most recent SEC Form 4 filing?
Bedrosian Camille L's most recent SEC Form 4 filing on Tracefour is dated Sep 14, 2026.
What is Bedrosian Camille L's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Bedrosian Camille L is listed as Chief Medical Officer.
What is Bedrosian Camille L's total buy and sell value in the current window?
Inside the rolling retention window, Bedrosian Camille L bought $0 and sold $689K based on SEC Form 4 filings.
What was Bedrosian Camille L's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 10,028 AMLX shares on 2026-09-10, worth $325K, per SEC Form 4 filings.